ccs1477
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2018 (NCT03568656)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
Mechanism of action
- Histone acetyltransferase PCAFINHIBITOR
KAT2B inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@H]1CC[C@H](n2c([C@@H]3CCCC(=O)N3c3ccc(F)c(F)c3)nc3cc(-c4c(C)noc4C)ccc32)CC1- Mol. weight
- 534.61 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4785363 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07096778 | Phase 2 | Dec 1, 2025 | CellCentric Ltd. |
| NCT04068597 | Phase 1/Phase 2 (Phase 2) | Aug 9, 2019 | Barts & The London NHS Trust, CellCentric Ltd. |
| NCT03568656 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2018 | CellCentric Ltd., University of London |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CellCentric Ltd. | For profit | 3 | 3 | 1 | 2018 |
| Barts & The London NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1